Imelasomeran

概览

Imelasomeran is a component of a bivalent COVID-19 mRNA vaccine encoding the viral spike protein of Omicron variant lineage BA.1.

作用机制

Moderna's COVID-19 mRNA vaccine is composed of synthetic nucleoside-modified messenger RNA (mRNA) encapsulated in Lipid nanoparticle (LNP) which codes for the full-length, pre-fusion stabilized spike protein (S) of SARS-CoV-2. The S glycoprotein is a large transmembrane protein that plays a critical role in viral attachment, fusion, and entry into the host cell. Upon vaccination, human cells express the SARS-CoV-2 S antigen and immune response to the S antigen is elicited, leading to protection against SARS-CoV-2. Imelasomeran is a component of one of Moderna's bivalent COVID-19 mRNA vaccines. It encodes the pre-fusion stabilized S glycoprotein of SARS-CoV-2 Omicron variant B.1.1.529 in order to elicit specific protection against this variant.

适应症

The Bivalent Moderna COVID-19 Vaccine (Original and Omicron BA.1) is a combination of imelasomeran and elasomeran (i.e. the monovalent Moderna COVID-19 Vaccine). It is indicated in Canada as a booster dose for the prevention of COVID-19. In patients 6-11 years of age, a dose of 25mcg may be given intramuscularly 6 months following completion of a primary vaccine series and/or previous booster dose. In patients ≥12 years of age, a dose of 50mcg may be given intramuscularly 4 months following completion of a primary vaccine series and/or previous booster dose.

• Coronavirus Disease 2019 (COVID‑19)